Zacks: Brokerages Anticipate Assembly Biosciences Inc (NASDAQ:ASMB) to Announce -$0.55 Earnings Per Share

Wall Street analysts forecast that Assembly Biosciences Inc (NASDAQ:ASMB) will post earnings per share of ($0.55) for the current quarter, Zacks reports. Four analysts have made estimates for Assembly Biosciences’ earnings, with the highest EPS estimate coming in at $0.17 and the lowest estimate coming in at ($0.84). Assembly Biosciences posted earnings of ($0.72) per share during the same quarter last year, which suggests a positive year over year growth rate of 23.6%. The firm is scheduled to report its next earnings report on Monday, August 3rd.

According to Zacks, analysts expect that Assembly Biosciences will report full year earnings of ($3.13) per share for the current year, with EPS estimates ranging from ($3.58) to ($2.32). For the next fiscal year, analysts forecast that the firm will post earnings of ($4.03) per share, with EPS estimates ranging from ($5.76) to ($3.22). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.98) by $0.22. Assembly Biosciences had a negative return on equity of 45.43% and a negative net margin of 601.75%. The business had revenue of $4.08 million during the quarter, compared to the consensus estimate of $3.82 million.

A number of equities research analysts have recently weighed in on the company. William Blair reiterated a “buy” rating on shares of Assembly Biosciences in a report on Thursday. BidaskClub upgraded Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a report on Friday. ValuEngine upgraded Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, April 8th. Zacks Investment Research lowered Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Mizuho restated a “buy” rating and set a $30.00 price objective on shares of Assembly Biosciences in a research report on Friday, May 8th. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $39.75.

Shares of NASDAQ ASMB traded up $0.65 during trading on Friday, reaching $23.81. The stock had a trading volume of 166,900 shares, compared to its average volume of 261,602. Assembly Biosciences has a one year low of $8.13 and a one year high of $25.07. The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.14 and a current ratio of 12.14. The stock has a market cap of $757.85 million, a PE ratio of -6.94 and a beta of 1.26. The firm’s 50 day moving average price is $20.86 and its two-hundred day moving average price is $18.82.

In other news, EVP Richard James Colonno sold 7,812 shares of the company’s stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $15.04, for a total value of $117,492.48. Following the completion of the sale, the executive vice president now owns 144,821 shares in the company, valued at $2,178,107.84. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 12.42% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Bank of Montreal Can raised its holdings in Assembly Biosciences by 34.8% in the 4th quarter. Bank of Montreal Can now owns 3,440 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 889 shares in the last quarter. BNP Paribas Arbitrage SA raised its holdings in Assembly Biosciences by 188.6% in the 1st quarter. BNP Paribas Arbitrage SA now owns 8,620 shares of the biopharmaceutical company’s stock valued at $128,000 after acquiring an additional 5,633 shares in the last quarter. Citigroup Inc. raised its holdings in Assembly Biosciences by 130.0% in the 4th quarter. Citigroup Inc. now owns 6,761 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 3,822 shares in the last quarter. Aperio Group LLC acquired a new position in Assembly Biosciences in the 1st quarter valued at approximately $149,000. Finally, Commonwealth Equity Services LLC acquired a new position in Assembly Biosciences in the 1st quarter valued at approximately $152,000. 88.34% of the stock is owned by hedge funds and other institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

See Also: Institutional Investors

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.